Apolipoprotein C-III in association with metabolic-dysfunction associated steatotic liver disease: A large, multicenter study

The available literature on the effect of apolipoprotein C-III (ApoC-III) inhibition in MASLD reveals inconsistencies. The aim of the present work was to examine levels of ApoC-III in the entire spectrum of metabolic-dysfunction associated steatotic liver disease (MASLD). This is a multicenter study...

Full description

Saved in:
Bibliographic Details
Published in:Clinical nutrition (Edinburgh, Scotland) Scotland), 2024-12, Vol.43 (12), p.101-108
Main Authors: Kouvari, Matina, Valenzuela-Vallejo, Laura, Guatibonza-Garcia, Valentina, Verrastro, Ornella, Axarloglou, Evangelos, Mylonakis, Sophia C., George, Jacob, Papatheodoridis, Georgios, Mingrone, Geltrude, Mantzoros, Christos S.
Format: Article
Language:English
Subjects:
Adult
Apolipoprotein
Apolipoprotein C-III - blood
Australia
Bariatric Surgery
Fatty Liver - blood
Fatty liver disease
Female
Greece - epidemiology
Humans
Italy
Lipids
Liver - pathology
Liver fibrosis
Male
Middle Aged
NAFLD
Triglycerides - blood
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The available literature on the effect of apolipoprotein C-III (ApoC-III) inhibition in MASLD reveals inconsistencies. The aim of the present work was to examine levels of ApoC-III in the entire spectrum of metabolic-dysfunction associated steatotic liver disease (MASLD). This is a multicenter study involving patients enrolled in two gastroenterology-hepatology clinics (Greece and Australia) and in a bariatric-metabolic surgery clinic (Italy), with liver biopsy before and after bariatric surgery or lifestyle modification. Comparing simple MASL to steatohepatitis (MASH) with fibrosis stage F ≥ 2 (at-risk MASH), revealed a marginally significant trend for decreased ApoC-III levels in the latter group (p = 0.07). Multi-adjusted analysis revealed an inverse association between ApoC-III and at-risk MASH (Odds Ratioper 1 mg/dL increase in ApoC-III = 0.91, 95 % Confidence Interval (0.83, 0.99)). ApoC-III interacted with triglycerides in predicting at-risk MASH (p-for-interaction = 0.002). Participants with ApoC-III > median (∼3.75 mg/dL) and normal triglycerides (triglyceridese≤150 mg/dL) had the lowest likelihood to present at-risk MASH (31.8 %) in contrast with participants with ApoC-III 
ISSN:0261-5614
1532-1983
1532-1983
DOI:10.1016/j.clnu.2024.10.007